Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Author: sugaradmin

1191-OR: Progressive Failure of Brown Adipose Tissue Remodeling Drives Metabolic Aging

June 7, 2026 by sugaradmin

Introduction and Objective: Aging is the strongest risk factor for T2D, yet how age-dependent changes in energy-regulating tissues drive metabolic decline remains unclear. Brown adipose tissue (BAT) plays a role in adaptive thermogenesis and glucose metabolism, but whether aging alters BAT remodeling in a stage-dependent manner is unknown.Methods: We performed integrated metabolic phenotyping and single-cell […]

Read More
DiabetesLeave a Comment on 1191-OR: Progressive Failure of Brown Adipose Tissue Remodeling Drives Metabolic Aging

2522-P: GPSM1 Controls Metabolism and Motor Function in Obesity via cAMP/PKA/YAP/TAZ-Mediated Mitochondrial Biogenesis

June 7, 2026 by sugaradmin

Introduction and Objective: The type 2 diabetes susceptibility gene GPSM1 is linked to impaired muscle function in patients, though its molecular mechanisms remain unknown. This study explores how GPSM1 regulates skeletal muscle metabolism and motor performance.Methods: Skeletal muscle-specific GPSM1 knockout (GPSM1MKO) mice were generated and maintained on either a standard chow or high-fat diet (HFD), […]

Read More
DiabetesLeave a Comment on 2522-P: GPSM1 Controls Metabolism and Motor Function in Obesity via cAMP/PKA/YAP/TAZ-Mediated Mitochondrial Biogenesis

2762-LB: Type 2 Diabetes Remission Rate and Change in Medication Burden after 12 Months of Intermittent Fasting

June 7, 2026 by sugaradmin

Introduction and Objective: Intermittent energy restriction (IER) and time-restricted eating (TRE) are two forms of intermittent fasting that may reduce diabetes medication needs in type 2 diabetes (T2D). However, head-to-head comparisons of IF approaches and trials using IF in T2D remain limited. We evaluated diabetes remission and pharmacologic de-intensification in a secondary analysis of a […]

Read More
DiabetesLeave a Comment on 2762-LB: Type 2 Diabetes Remission Rate and Change in Medication Burden after 12 Months of Intermittent Fasting

2232-P: Multiomics Integration Identifies Distinct Molecular Endotypes of Atypical Diabetes

June 7, 2026 by sugaradmin

Introduction and Objective: A convergence of dysregulated metabolic, polygenic and environmental factors drives the pathophysiology of diabetes mellitus. We performed unsupervised integration of transcriptomic and metabolomic data among participants in the Rare and Atypical Diabetes Network (RADIANT) to identify distinct endotypes of atypical diabetes.Methods: This cross-sectional, observational study included RADIANT participants meeting predefined atypical diabetes […]

Read More
DiabetesLeave a Comment on 2232-P: Multiomics Integration Identifies Distinct Molecular Endotypes of Atypical Diabetes

2521-P: Physical Inactivity Induced by Bed Rest Reduces Muscle but Not Hepatic or Adipose Tissue Insulin Sensitivity in Older Adults with or without Pre- or Type 2 Diabetes

June 6, 2026 by sugaradmin

Introduction and Objective: Older adults with pre-diabetes or type 2 diabetes experience hospitalization and bed rest more frequently than healthy older adults. However, the impact of physical inactivity induced by bed rest on insulin sensitivity in older adults with pre- or type 2 diabetes is unknown. To address this, we conducted a 10-day bed rest […]

Read More
DiabetesLeave a Comment on 2521-P: Physical Inactivity Induced by Bed Rest Reduces Muscle but Not Hepatic or Adipose Tissue Insulin Sensitivity in Older Adults with or without Pre- or Type 2 Diabetes

2231-P: RECLASS-T1D: Real-World Evaluation of AABBCC Criteria for Diabetes Classification: Experience from 6.7 Million U.S. Patients

June 6, 2026 by sugaradmin

Introduction and Objective: The AABBCC approach (Age <35 years, Autoimmunity [family or personal history], BMI <25 kg/m2, Background, Control [not responding to oral agents], and Comorbidities) has been proposed by the American Diabetes Association to help distinguish between diabetes types. This study examined the reclassification rates from prediabetes or type 2 diabetes (T2D) to type […]

Read More
DiabetesLeave a Comment on 2231-P: RECLASS-T1D: Real-World Evaluation of AABBCC Criteria for Diabetes Classification: Experience from 6.7 Million U.S. Patients

1554-P: Barriers to Treatment Adherence among Latino Adults with Type 2 Diabetes: Baseline Findings from the REACH-Es Pilot Study

June 6, 2026 by sugaradmin

Introduction and Objective: Suboptimal diabetes medication adherence disproportionately affects Latino adults with type 2 diabetes (T2D). REACH is a text messaging platform based on the Information-Motivation-Behavioral skills model that addresses barriers to medication adherence. REACH was adapted into Spanish (REACH-Español) and is being evaluated in a 6-month pilot RCT among 70 Latino adults with T2D. […]

Read More
DiabetesLeave a Comment on 1554-P: Barriers to Treatment Adherence among Latino Adults with Type 2 Diabetes: Baseline Findings from the REACH-Es Pilot Study

2230-P: Profile of Monogenic Diabetes in a Predominantly Hispanic Pediatric Population: Insights from a Single-Center Cohort

June 6, 2026 by sugaradmin

Introduction and Objective: Maturity Onset Diabetes of the Young (MODY) is an underrecognized and misdiagnosed form of diabetes that refers to a group of single gene causes of diabetes with a strong autosomal dominant inheritance. Fourteen (14) gene mutations have been identified accounting for 1-5% of all diabetes cases. Identification of MODY is necessary for […]

Read More
DiabetesLeave a Comment on 2230-P: Profile of Monogenic Diabetes in a Predominantly Hispanic Pediatric Population: Insights from a Single-Center Cohort

1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders

June 6, 2026 by sugaradmin

Introduction and Objective: Chronic opioid use is associated with high risk of overdose and developing substance use disorder. GLP-1RAs may influence reward-related neurobehavioral pathways, however, their real-world effects on opioid-related outcomes are unclear. We evaluated the association between GLP-1RA use and risk of opioid overdose among individuals with chronic opioid use.Methods: Using US claims data, […]

Read More
DiabetesLeave a Comment on 1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders

2229-P: Association between C-Reactive Protein–Triglyceride–Glucose Index and New-Onset Chronic Disease Incidence and Mortality: Evidence from Multinational Cohorts

June 6, 2026 by sugaradmin

Introduction and Objective: The C-reactive protein-triglyceride-glucose index (CTI) is a composite biomarker reflecting insulin resistance and systemic inflammation. Large-scale evidence linking CTI to multiple chronic diseases and cause-specific mortality remains limited.Methods: We conducted a multicenter cohort study of middle-aged and older adults using the China Health and Retirement Longitudinal Study (CHARLS, n=5366) and US National […]

Read More
DiabetesLeave a Comment on 2229-P: Association between C-Reactive Protein–Triglyceride–Glucose Index and New-Onset Chronic Disease Incidence and Mortality: Evidence from Multinational Cohorts

Posts navigation

Older posts
Newer posts

Recent Posts

  • ‘Ozempic Feet:’ What Causes This Unusual GLP-1 Side Effect?
  • Depo-Provera, IUDs Tied to Higher Brain Tumor Risk
  • Trends in self-reported current diabetes care use, socioeconomic inequalities, and associated factors in Japan: evidence from the Comprehensive Survey of Living Conditions (1986-2022)
  • Bryan Johnson Diagnosed with Autoimmune Gastritis
  • Sam Neill, ‘Jurassic Park’ Star, Dies at 78

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness